New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 6, 2014
13:57 EDTLLYLilly to present data from bemaciclib as potential treatment for breast cancer
Eli Lilly and Company will present early-stage data from several targeted cancer therapies including bemaciclib, its oral, cell-cycle inhibitor of CDK4/6 that make up its diverse clinical oncology pipeline during the American Association for Cancer Research, AACR, Annual Meeting 2014 held in San Diego, Calif. from April 5 9. Data from bemaciclib, Lilly's CDK4/6 inhibitor LY2835219 as a potential treatment for metastatic breast cancer, has been accepted as a late-breaking presentation that will be included at AACR's Clinical Trials Symposium and will be featured in an official AACR-sponsored press conference. "The CDK4/6 pathway is one of the most commonly implicated pathways in all cancers, making it an important area for research," said Richard Gaynor, M.D., senior vice president of product development and medical affairs for Lilly Oncology. "The single-agent activity we've observed for bemaciclib is encouraging in this setting and we believe the data support the need for further development in metastatic breast cancer."
News For LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 21, 2015
10:16 EDTLLYLeerink biopharma analysts hold an analyst/industry conference call
Analyst Fernandez, along with Dr. Paul Gurbel and Dr. Richard Becker, discuss AstraZeneca's PEGASUS trial and the current use of Brilinta and dual antiplatelet therapy for prevention of CV disease and implications of the recently completed DAPT trial on an Analyst/Industry conference call to be held on January 21 at 1:30 pm.
January 15, 2015
11:20 EDTLLYGoldman cuts J&J to sell citing competitive pressures
Subscribe for More Information
10:00 EDTLLYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:07 EDTLLYEli Lilly upgraded at Goldman
As previously reported, Goldman upgraded Eli Lilly to Neutral from Sell. The firm upgraded shares based on new product launches and pipeline assets, and cost reductions. Price target is $70.
06:44 EDTLLYEli Lilly upgraded to Neutral from Sell at Goldman
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use